Navigation Links
New data obtained on liposomes employed in drug encapsulation and gene therapies
Date:2/8/2011

This release is available in Spanish.

University of Granada scientists and the Spanish Higher Institute for Scientific Research (CSIC) have made significant progress in understanding lipid membranes, which are extensively employed in the development of cosmetic and drug products, and which have potential application in the field of nanotechnology.

Phospholipid vesicles (liposomes) are colloidal systems that arise considerable interest from the pharmaceutical, cosmetic and food industry, since they are biocompatible in protein, nucleic acid, drug, etc encapsulation. Further, from a scientific perspective, liposomes are considered a model system of cell membranes that have been implemented in the study of biological transport processes through cell membranes, as well as in the study of aggregation processes induced by biological substances, etc.

To develop products of biotechnological interest, understanding thoroughly the electrostatic properties of these membranes is necessary. This was the purpose of Alberto Martn Molina and Csar Rodrguez Beas, from the Department of Applied Physics of the University of Granada, and Jordi Faraudo from the Instituto de Ciencias de Materiales in Barcelona (CSIC), authors of a study recently published in the journal Physical Review Letters (Vol. 104; pp 168103 (2010). 104, pp 168103 (2010)).

Inverting its Electrostatic Charge

This study discloses why certain lipid membranes can invert their surface electrostatic charge, that is, why these membranes have negative charge, but they can function as positive charge material in specific circumstances. This type of membranes are extensively employed in gene therapies.

Such behaviour is due to the fact that the interphase of these membranes in water is
'/>"/>

Contact: Alberto Martn Molina
almartin@ugr.es
34-958-240-025
University of Granada
Source:Eurekalert

Page: 1 2

Related medicine news :

1. New clue in leukemia mystery: Researchers identify poison employed by deadly enzyme mutations
2. Immigrants with disabilities more frequently employed than US-born persons with disabilities
3. CED Solutions Offers Free 3-Day Technical Windows 7 Certification Course for Unemployed Individuals
4. Generic drug may improve the effectiveness of cancer nanotherapies
5. New Therapies Offer Insight Into Battling Deadly Melanomas
6. Many U.S. Hospices Provide Alternative Therapies: Report
7. Link between signaling molecules could point way to therapies for epilepsy, stroke, other diseases
8. Many Brain Tumor Patients Turn to Alternative Therapies
9. John Theurer Cancer Center presents studies on promising therapies for aggressive blood cancers
10. New therapies and gene target advance the treatment and understanding of hard-to-treat leukemias
11. Alternative therapies may leave asthmatics gasping
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... ... 30, 2015 , ... Between 2012 and 2014 HIV infection rates rose from ... on June 17th. Those untreated heroin use disorders share their needles and spread the ... needles throughout the community. Ultimately Florida’s HIV infection rates have bolstered to 23 percent ...
(Date:7/30/2015)... Dana Point, CA (PRWEB) , ... July 30, 2015 , ... ... the highest honors available, including the very rare “no recommendations.” No recommendations means CARF ... full compliance; this is a notation that less than 3% of all facilities receive. ...
(Date:7/30/2015)... Alexandria, VA (PRWEB) , ... July 30, 2015 ... ... applauds Drug Enforcement Administration (DEA) Acting Administrator Chuck Rosenberg’s announcement of the reinstitution ... been scheduled for Saturday, September 26, 2015 from 10:00 AM to 2:00 PM ...
(Date:7/30/2015)... ... July 30, 2015 , ... The Tisch ... Institute Designation , The Tisch Cancer Institute (TCI) at the Icahn School of ... center. TCI joins an elite group of 69 cancer institutions nationwide that have ...
(Date:7/30/2015)... PA (PRWEB) , ... July 30, 2015 , ... ... inventor from Texas, has designed a personal-care device that makes it easy to apply ... Buddy” could eliminate the need for assistance when applying lotion or medication to the ...
Breaking Medicine News(10 mins):Health News:HIV Rates Rise in S. Florida, Harbor Village Comments on Health News Florida's Recent Article 2Health News:HIV Rates Rise in S. Florida, Harbor Village Comments on Health News Florida's Recent Article 3Health News:Ocean Hills Recovery Receives Accreditation from CARF International 2Health News:AAPCC Supports National Prescription Drug Take-Back Day 2Health News:AAPCC Supports National Prescription Drug Take-Back Day 3Health News:The Tisch Cancer Institute at Icahn School of Medicine at Mount Sinai Earns National Cancer Institute Designation 2Health News:The Tisch Cancer Institute at Icahn School of Medicine at Mount Sinai Earns National Cancer Institute Designation 3Health News:The Tisch Cancer Institute at Icahn School of Medicine at Mount Sinai Earns National Cancer Institute Designation 4Health News:The Tisch Cancer Institute at Icahn School of Medicine at Mount Sinai Earns National Cancer Institute Designation 5Health News:The Tisch Cancer Institute at Icahn School of Medicine at Mount Sinai Earns National Cancer Institute Designation 6Health News:InventHelp® Client Patents “My Back Buddy” – Device Could Apply Lotion to Hard-to-Reach Areas Easily 2
... for the Fourth Quarter was $ 0.28 per share ... the Year ... End, LANCASTER, Pa., Oct. 11 Herley Industries,Inc. (Nasdaq: HRLY ) today reported ... income during the fourth quarter of 2007 was $3.8 million or $.28,per share, as compared ...
... a simple tool that can improve the effectiveness of ... result in dramatic improvements in health and safety. , ... with color images of the medication to be taken ... in a patient,s native language if the patient does ...
... Oct. 11 The law firm of Kohn, Swift ... has been,commenced against Pall Corporation ("Pall" or the "Company") ... States District Court for the Eastern,District of New York, ... of all investors who purchased Pall securities between April,20, ...
... Tahoe, CA, October 11, 2007 Cancer researchers have ... after the use of therapies designed to stop the ... cell growth. New research has now detected that androgen-synthesizing ... cancer cells may develop the capacity to produce their ...
... implicated in prostate and breast cancer development may also ... Researchers at the Kimmel Cancer Center at Jefferson in ... normally applies the brakes on a cancer-causing gene ... Though the work is preliminary, the scientists say, the ...
... CHESHIRE, Conn., Oct. 11 Alexion,Pharmaceuticals, Inc. (Nasdaq: ... conference call and audio web cast on Thursday, October ... with the release of its,financial results for the third ... results at 6:30 a.m. ET on Thursday,October 25, 2007. ...
Cached Medicine News:Health News:Herley Reports 4th Quarter and Year-End Results 2Health News:Herley Reports 4th Quarter and Year-End Results 3Health News:Herley Reports 4th Quarter and Year-End Results 4Health News:Herley Reports 4th Quarter and Year-End Results 5Health News:Herley Reports 4th Quarter and Year-End Results 6Health News:Herley Reports 4th Quarter and Year-End Results 7Health News:Herley Reports 4th Quarter and Year-End Results 8Health News:Herley Reports 4th Quarter and Year-End Results 9Health News:Herley Reports 4th Quarter and Year-End Results 10Health News:Herley Reports 4th Quarter and Year-End Results 11Health News:Improving doctor-patient communication yields significant health benefits 2Health News:Improving doctor-patient communication yields significant health benefits 3Health News:Improving doctor-patient communication yields significant health benefits 4Health News:Kohn, Swift & Graf, P.C. Announces Commencement of Lawsuit Against Pall Corporation-PLL 2Health News:Kohn, Swift & Graf, P.C. Announces Commencement of Lawsuit Against Pall Corporation-PLL 3Health News:New research may show why some prostate cancer recurs after treatment 2Health News:New research may show why some prostate cancer recurs after treatment 3Health News:Jefferson scientists find protein may be key in developing deadly form of pancreatic cancer 2
(Date:7/30/2015)...  Medimetriks Pharmaceuticals, Inc. announced today that its ... study for Ozenoxacin, a novel bactericidal non-fluorinated quinolone ... U.S. rights to Ozenoxacin 1% cream.  ... with an emphasis on U.S. patients, involved 412 ... older with a clinical diagnosis of bullous or ...
(Date:7/30/2015)... , July 30, 2015 Vermillion, ... on gynecologic disease, announced today it will ... after the market close on Thursday, August ... call and webcast at 4:30pm Eastern.Conference Call ... at 4:30pm Eastern/1:30pm Pacific  Domestic: ...
(Date:7/30/2015)... , July 30, 2015  Big Cloud Analytics, ... analytics technology, announces it is working with Intel ... for the new Lockheed Martin Healthcare Technology Alliance. ... health information technology providers, medical technology companies and ... and innovation to improve care in rapidly evolving ...
Breaking Medicine Technology:Medimetriks Pharmaceuticals, Inc. Announces Completion of the Second Successful Pivotal Phase III Study for Ozenoxacin 2Medimetriks Pharmaceuticals, Inc. Announces Completion of the Second Successful Pivotal Phase III Study for Ozenoxacin 3Big Cloud Analytics Develop Internet of Things (IoT) Solutions with Intel Supporting Launch of Lockheed Martin Healthcare Technology Alliance 2Big Cloud Analytics Develop Internet of Things (IoT) Solutions with Intel Supporting Launch of Lockheed Martin Healthcare Technology Alliance 3
Quantitative determination of Fibrinogen by STA Analyzers (Clauss Method). Freeze-dried human thrombin (~100NIH units/mL) with heparin inhibitor and calcium....
Determination of Prothrombin Time (PT) by STA Analyzers (ISI~1.3).Freeze-dried rabbit brain thromboplastin with heparin inhibitor....
The ALB method used on the Dimension clinical chemistry system is an in vitro diagnostic test intended for the quantitative determination of albumin in serum...
The PHOS method used on the Dimension clinical chemistry system is an in vitro diagnostic test intended for the quantitative determination of phosphorus in serum....
Medicine Products: